Hemophilia A - Pipeline Review, H1 2014
出 版 商：Global Markets Direct
出版日期：2014/02/28
頁 數：174頁
文件格式：PDF
價 格：
USD 2,000 (Single-User License)
USD 4,000 (Multi-User License)
USD 6,000 (Global-User License)
USD 4,000 (Multi-User License)
USD 6,000 (Global-User License)
Hemophilia A - Pipeline Review, H1 2014
Summary
Global Markets Direct’s, ‘Hemophilia A - Pipeline Review, H1 2014’, provides an overview of the Hemophilia A’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Hemophilia A, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hemophilia A and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Hemophilia A
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Hemophilia A and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Hemophilia A products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Hemophilia A pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Hemophilia A
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Hemophilia A pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Summary
Global Markets Direct’s, ‘Hemophilia A - Pipeline Review, H1 2014’, provides an overview of the Hemophilia A’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Hemophilia A, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hemophilia A and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Hemophilia A
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Hemophilia A and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Hemophilia A products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Hemophilia A pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Hemophilia A
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Hemophilia A pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Hemophilia A Overview 8
Therapeutics Development 9
Pipeline Products for Hemophilia A - Overview 9
Pipeline Products for Hemophilia A - Comparative Analysis 10
Hemophilia A - Therapeutics under Development by Companies 11
Hemophilia A - Therapeutics under Investigation by Universities/Institutes 15
Hemophilia A - Pipeline Products Glance 16
Late Stage Products 16
Clinical Stage Products 17
Early Stage Products 18
Unknown Stage Products 19
Hemophilia A - Products under Development by Companies 20
Hemophilia A - Products under Investigation by Universities/Institutes 23
Hemophilia A - Companies Involved in Therapeutics Development 24
Baxter International Inc. 24
Biogen Idec Inc. 25
AstraZeneca PLC 26
Cangene Corporation 27
Lentigen Corporation 28
Sangamo BioSciences, Inc. 29
Pharming Group N.V. 30
Novo Nordisk A/S 31
Grifols, S.A. 32
BioMarin Pharmaceutical Inc. 33
Chugai Pharmaceutical Co., Ltd. 34
rEVO Biologics 35
Octapharma AG 36
Pfizer Inc. 37
Bayer AG 38
Prolor Biotech, Inc. 39
ReGenX Biosciences, LLC 40
Alnylam Pharmaceuticals, Inc. 41
CSL Limited 42
Green Cross Corporation 43
Amarna Therapeutics B.V. 44
EpiVax, Inc. 45
Expression Therapeutics LLC 46
Asklepios BioPharmaceutical, Inc. 47
Amunix, Inc. 48
Inserm Transfert SA 49
Selecta Biosciences, Inc. 50
Celtic Pharmaceutical Holdings L.P. 51
Inbiopro Solutions Pvt. Ltd. 52
International Biotechnology Center Generium 53
AlphaMab Co., Ltd 54
Dong-A Socio Holdings Co Ltd 55
Hemophilia A - Therapeutics Assessment 56
Assessment by Monotherapy Products 56
Assessment by Target 57
Assessment by Mechanism of Action 60
Assessment by Route of Administration 63
Assessment by Molecule Type 65
Drug Profiles 68
turoctocog alfa - Drug Profile 68
antihemophilic factor-Fc (recombinant) - Drug Profile 70
OBI-1 - Drug Profile 72
hcl-rFVIII - Drug Profile 74
GNR-001 - Drug Profile 76
antihemophilic factor-Fc (recombinant) - Drug Profile 77
OBI-1 - Drug Profile 79
BAX-855 - Drug Profile 81
hcl-rFVIII - Drug Profile 82
BAY-818973 - Drug Profile 84
NN-7088 - Drug Profile 86
BAY-949027 - Drug Profile 87
LR-769 - Drug Profile 88
CSL-627 - Drug Profile 90
beroctocog alfa - Drug Profile 91
BAX-817 - Drug Profile 92
GNR-002 - Drug Profile 94
oprelvekin - Drug Profile 95
ACE-910 - Drug Profile 96
CSL-689 - Drug Profile 97
PF-05280602 - Drug Profile 99
concizumab - Drug Profile 100
MOD-5017 - Drug Profile 101
ALN-AT3 - Drug Profile 102
eptacog alfa biosimilar - Drug Profile 103
ZFP Nucleases For Hemophilia - Drug Profile 104
LG-889 - Drug Profile 106
IB1-007 - Drug Profile 107
IB1-008 - Drug Profile 108
DA-3808 - Drug Profile 109
PEG-rFVIII-PI Complex - Drug Profile 110
Human Coagulation Factor-VIII - Drug Profile 111
Deimmunized FVIII - Drug Profile 112
Gene Therapy To Activate Factor VIII For Hemophilia A - Drug Profile 113
Factor VIII Program - Drug Profile 114
Long Acting Coagulation Factor VIIa - Drug Profile 115
Gene Therapy For Hemophilia A - Drug Profile 117
SEL-201 - Drug Profile 118
Factor VIII Gene Therapy Program - Drug Profile 119
TheraPEG-FVIII - Drug Profile 120
moroctocog alfa biosimilar - Drug Profile 121
Lentiviral Based Gene Therapy - Drug Profile 122
beroctocog alfa - Drug Profile 123
LG-888 - Drug Profile 124
rhFactor VIII - Drug Profile 125
BNP-FVIII - Drug Profile 126
AZ-10047130 - Drug Profile 127
AZ-10214075 - Drug Profile 128
AZ-10776241 - Drug Profile 129
Gene Therapy For Hemophilia A - Drug Profile 130
IBPH-001-OC - Drug Profile 131
beroctocog alfa - Drug Profile 132
SVF-VIIa - Drug Profile 133
Hemophilia A - Recent Pipeline Updates 134
Hemophilia A - Dormant Projects 157
Hemophilia A - Discontinued Products 158
Hemophilia A - Product Development Milestones 159
Featured News & Press Releases 159
Appendix 169
Methodology 169
Coverage 169
Secondary Research 169
Primary Research 169
Expert Panel Validation 169
Contact Us 170
Disclaimer 170
List of Tables
Number of Products under Development for Hemophilia A, H1 2014 13
Number of Products under Development for Hemophilia A - Comparative Analysis, H1 2014 14
Number of Products under Development by Companies, H1 2014 16
Number of Products under Development by Companies, H1 2014 (Contd..1) 17
Number of Products under Development by Companies, H1 2014 (Contd..2) 18
Number of Products under Investigation by Universities/Institutes, H1 2014 19
Comparative Analysis by Late Stage Development, H1 2014 20
Comparative Analysis by Clinical Stage Development, H1 2014 21
Comparative Analysis by Early Stage Development, H1 2014 22
Comparative Analysis by Unknown Stage Development, H1 2014 23
Products under Development by Companies, H1 2014 24
Products under Development by Companies, H1 2014 (Contd..1) 25
Products under Development by Companies, H1 2014 (Contd..2) 26
Products under Investigation by Universities/Institutes, H1 2014 27
Hemophilia A - Pipeline by Baxter International Inc., H1 2014 28
Hemophilia A - Pipeline by Biogen Idec Inc., H1 2014 29
Hemophilia A - Pipeline by AstraZeneca PLC, H1 2014 30
Hemophilia A - Pipeline by Cangene Corporation, H1 2014 31
Hemophilia A - Pipeline by Lentigen Corporation, H1 2014 32
Hemophilia A - Pipeline by Sangamo BioSciences, Inc., H1 2014 33
Hemophilia A - Pipeline by Pharming Group N.V., H1 2014 34
Hemophilia A - Pipeline by Novo Nordisk A/S, H1 2014 35
Hemophilia A - Pipeline by Grifols, S.A., H1 2014 36
Hemophilia A - Pipeline by BioMarin Pharmaceutical Inc., H1 2014 37
Hemophilia A - Pipeline by Chugai Pharmaceutical Co., Ltd., H1 2014 38
Hemophilia A - Pipeline by rEVO Biologics, H1 2014 39
Hemophilia A - Pipeline by Octapharma AG, H1 2014 40
Hemophilia A - Pipeline by Pfizer Inc., H1 2014 41
Hemophilia A - Pipeline by Bayer AG, H1 2014 42
Hemophilia A - Pipeline by Prolor Biotech, Inc., H1 2014 43
Hemophilia A - Pipeline by ReGenX Biosciences, LLC, H1 2014 44
Hemophilia A - Pipeline by Alnylam Pharmaceuticals, Inc., H1 2014 45
Hemophilia A - Pipeline by CSL Limited, H1 2014 46
Hemophilia A - Pipeline by Green Cross Corporation, H1 2014 47
Hemophilia A - Pipeline by Amarna Therapeutics B.V., H1 2014 48
Hemophilia A - Pipeline by EpiVax, Inc., H1 2014 49
Hemophilia A - Pipeline by Expression Therapeutics LLC, H1 2014 50
Hemophilia A - Pipeline by Asklepios BioPharmaceutical, Inc., H1 2014 51
Hemophilia A - Pipeline by Amunix, Inc., H1 2014 52
Hemophilia A - Pipeline by Inserm Transfert SA, H1 2014 53
Hemophilia A - Pipeline by Selecta Biosciences, Inc., H1 2014 54
Hemophilia A - Pipeline by Celtic Pharmaceutical Holdings L.P., H1 2014 55
Hemophilia A - Pipeline by Inbiopro Solutions Pvt. Ltd., H1 2014 56
Hemophilia A - Pipeline by International Biotechnology Center Generium, H1 2014 57
Hemophilia A - Pipeline by AlphaMab Co., Ltd, H1 2014 58
Hemophilia A - Pipeline by Dong-A Socio Holdings Co Ltd, H1 2014 59
Assessment by Monotherapy Products, H1 2014 60
Number of Products by Stage and Target, H1 2014 63
Number of Products by Stage and Mechanism of Action, H1 2014 66
Number of Products by Stage and Route of Administration, H1 2014 68
Number of Products by Stage and Molecule Type, H1 2014 71
Hemophilia A Therapeutics - Recent Pipeline Updates, H1 2014 138
Hemophilia A - Dormant Projects, H1 2014 161
Hemophilia A - Discontinued Products, H1 2014 162
List of Figures
Number of Products under Development for Hemophilia A, H1 2014 13
Number of Products under Development for Hemophilia A - Comparative Analysis, H1 2014 14
Number of Products under Development by Companies, H1 2014 15
Comparative Analysis by Late Stage Development, H1 2014 20
Comparative Analysis by Clinical Stage Development, H1 2014 21
Comparative Analysis by Early Stage Products, H1 2014 22
Assessment by Monotherapy Products, H1 2014 60
Number of Products by Top 10 Target, H1 2014 61
Number of Products by Stage and Top 10 Target, H1 2014 62
Number of Products by Top 10 Mechanism of Action, H1 2014 64
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 65
Number of Products by Top 10 Route of Administration, H1 2014 67
Number of Products by Stage and Top 10 Route of Administration, H1 2014 68
Number of Products by Top 10 Molecule Type, H1 2014 69
Number of Products by Stage and Top 10 Molecule Type, H1 2014 70
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Hemophilia A Overview 8
Therapeutics Development 9
Pipeline Products for Hemophilia A - Overview 9
Pipeline Products for Hemophilia A - Comparative Analysis 10
Hemophilia A - Therapeutics under Development by Companies 11
Hemophilia A - Therapeutics under Investigation by Universities/Institutes 15
Hemophilia A - Pipeline Products Glance 16
Late Stage Products 16
Clinical Stage Products 17
Early Stage Products 18
Unknown Stage Products 19
Hemophilia A - Products under Development by Companies 20
Hemophilia A - Products under Investigation by Universities/Institutes 23
Hemophilia A - Companies Involved in Therapeutics Development 24
Baxter International Inc. 24
Biogen Idec Inc. 25
AstraZeneca PLC 26
Cangene Corporation 27
Lentigen Corporation 28
Sangamo BioSciences, Inc. 29
Pharming Group N.V. 30
Novo Nordisk A/S 31
Grifols, S.A. 32
BioMarin Pharmaceutical Inc. 33
Chugai Pharmaceutical Co., Ltd. 34
rEVO Biologics 35
Octapharma AG 36
Pfizer Inc. 37
Bayer AG 38
Prolor Biotech, Inc. 39
ReGenX Biosciences, LLC 40
Alnylam Pharmaceuticals, Inc. 41
CSL Limited 42
Green Cross Corporation 43
Amarna Therapeutics B.V. 44
EpiVax, Inc. 45
Expression Therapeutics LLC 46
Asklepios BioPharmaceutical, Inc. 47
Amunix, Inc. 48
Inserm Transfert SA 49
Selecta Biosciences, Inc. 50
Celtic Pharmaceutical Holdings L.P. 51
Inbiopro Solutions Pvt. Ltd. 52
International Biotechnology Center Generium 53
AlphaMab Co., Ltd 54
Dong-A Socio Holdings Co Ltd 55
Hemophilia A - Therapeutics Assessment 56
Assessment by Monotherapy Products 56
Assessment by Target 57
Assessment by Mechanism of Action 60
Assessment by Route of Administration 63
Assessment by Molecule Type 65
Drug Profiles 68
turoctocog alfa - Drug Profile 68
antihemophilic factor-Fc (recombinant) - Drug Profile 70
OBI-1 - Drug Profile 72
hcl-rFVIII - Drug Profile 74
GNR-001 - Drug Profile 76
antihemophilic factor-Fc (recombinant) - Drug Profile 77
OBI-1 - Drug Profile 79
BAX-855 - Drug Profile 81
hcl-rFVIII - Drug Profile 82
BAY-818973 - Drug Profile 84
NN-7088 - Drug Profile 86
BAY-949027 - Drug Profile 87
LR-769 - Drug Profile 88
CSL-627 - Drug Profile 90
beroctocog alfa - Drug Profile 91
BAX-817 - Drug Profile 92
GNR-002 - Drug Profile 94
oprelvekin - Drug Profile 95
ACE-910 - Drug Profile 96
CSL-689 - Drug Profile 97
PF-05280602 - Drug Profile 99
concizumab - Drug Profile 100
MOD-5017 - Drug Profile 101
ALN-AT3 - Drug Profile 102
eptacog alfa biosimilar - Drug Profile 103
ZFP Nucleases For Hemophilia - Drug Profile 104
LG-889 - Drug Profile 106
IB1-007 - Drug Profile 107
IB1-008 - Drug Profile 108
DA-3808 - Drug Profile 109
PEG-rFVIII-PI Complex - Drug Profile 110
Human Coagulation Factor-VIII - Drug Profile 111
Deimmunized FVIII - Drug Profile 112
Gene Therapy To Activate Factor VIII For Hemophilia A - Drug Profile 113
Factor VIII Program - Drug Profile 114
Long Acting Coagulation Factor VIIa - Drug Profile 115
Gene Therapy For Hemophilia A - Drug Profile 117
SEL-201 - Drug Profile 118
Factor VIII Gene Therapy Program - Drug Profile 119
TheraPEG-FVIII - Drug Profile 120
moroctocog alfa biosimilar - Drug Profile 121
Lentiviral Based Gene Therapy - Drug Profile 122
beroctocog alfa - Drug Profile 123
LG-888 - Drug Profile 124
rhFactor VIII - Drug Profile 125
BNP-FVIII - Drug Profile 126
AZ-10047130 - Drug Profile 127
AZ-10214075 - Drug Profile 128
AZ-10776241 - Drug Profile 129
Gene Therapy For Hemophilia A - Drug Profile 130
IBPH-001-OC - Drug Profile 131
beroctocog alfa - Drug Profile 132
SVF-VIIa - Drug Profile 133
Hemophilia A - Recent Pipeline Updates 134
Hemophilia A - Dormant Projects 157
Hemophilia A - Discontinued Products 158
Hemophilia A - Product Development Milestones 159
Featured News & Press Releases 159
Appendix 169
Methodology 169
Coverage 169
Secondary Research 169
Primary Research 169
Expert Panel Validation 169
Contact Us 170
Disclaimer 170
List of Tables
Number of Products under Development for Hemophilia A, H1 2014 13
Number of Products under Development for Hemophilia A - Comparative Analysis, H1 2014 14
Number of Products under Development by Companies, H1 2014 16
Number of Products under Development by Companies, H1 2014 (Contd..1) 17
Number of Products under Development by Companies, H1 2014 (Contd..2) 18
Number of Products under Investigation by Universities/Institutes, H1 2014 19
Comparative Analysis by Late Stage Development, H1 2014 20
Comparative Analysis by Clinical Stage Development, H1 2014 21
Comparative Analysis by Early Stage Development, H1 2014 22
Comparative Analysis by Unknown Stage Development, H1 2014 23
Products under Development by Companies, H1 2014 24
Products under Development by Companies, H1 2014 (Contd..1) 25
Products under Development by Companies, H1 2014 (Contd..2) 26
Products under Investigation by Universities/Institutes, H1 2014 27
Hemophilia A - Pipeline by Baxter International Inc., H1 2014 28
Hemophilia A - Pipeline by Biogen Idec Inc., H1 2014 29
Hemophilia A - Pipeline by AstraZeneca PLC, H1 2014 30
Hemophilia A - Pipeline by Cangene Corporation, H1 2014 31
Hemophilia A - Pipeline by Lentigen Corporation, H1 2014 32
Hemophilia A - Pipeline by Sangamo BioSciences, Inc., H1 2014 33
Hemophilia A - Pipeline by Pharming Group N.V., H1 2014 34
Hemophilia A - Pipeline by Novo Nordisk A/S, H1 2014 35
Hemophilia A - Pipeline by Grifols, S.A., H1 2014 36
Hemophilia A - Pipeline by BioMarin Pharmaceutical Inc., H1 2014 37
Hemophilia A - Pipeline by Chugai Pharmaceutical Co., Ltd., H1 2014 38
Hemophilia A - Pipeline by rEVO Biologics, H1 2014 39
Hemophilia A - Pipeline by Octapharma AG, H1 2014 40
Hemophilia A - Pipeline by Pfizer Inc., H1 2014 41
Hemophilia A - Pipeline by Bayer AG, H1 2014 42
Hemophilia A - Pipeline by Prolor Biotech, Inc., H1 2014 43
Hemophilia A - Pipeline by ReGenX Biosciences, LLC, H1 2014 44
Hemophilia A - Pipeline by Alnylam Pharmaceuticals, Inc., H1 2014 45
Hemophilia A - Pipeline by CSL Limited, H1 2014 46
Hemophilia A - Pipeline by Green Cross Corporation, H1 2014 47
Hemophilia A - Pipeline by Amarna Therapeutics B.V., H1 2014 48
Hemophilia A - Pipeline by EpiVax, Inc., H1 2014 49
Hemophilia A - Pipeline by Expression Therapeutics LLC, H1 2014 50
Hemophilia A - Pipeline by Asklepios BioPharmaceutical, Inc., H1 2014 51
Hemophilia A - Pipeline by Amunix, Inc., H1 2014 52
Hemophilia A - Pipeline by Inserm Transfert SA, H1 2014 53
Hemophilia A - Pipeline by Selecta Biosciences, Inc., H1 2014 54
Hemophilia A - Pipeline by Celtic Pharmaceutical Holdings L.P., H1 2014 55
Hemophilia A - Pipeline by Inbiopro Solutions Pvt. Ltd., H1 2014 56
Hemophilia A - Pipeline by International Biotechnology Center Generium, H1 2014 57
Hemophilia A - Pipeline by AlphaMab Co., Ltd, H1 2014 58
Hemophilia A - Pipeline by Dong-A Socio Holdings Co Ltd, H1 2014 59
Assessment by Monotherapy Products, H1 2014 60
Number of Products by Stage and Target, H1 2014 63
Number of Products by Stage and Mechanism of Action, H1 2014 66
Number of Products by Stage and Route of Administration, H1 2014 68
Number of Products by Stage and Molecule Type, H1 2014 71
Hemophilia A Therapeutics - Recent Pipeline Updates, H1 2014 138
Hemophilia A - Dormant Projects, H1 2014 161
Hemophilia A - Discontinued Products, H1 2014 162
List of Figures
Number of Products under Development for Hemophilia A, H1 2014 13
Number of Products under Development for Hemophilia A - Comparative Analysis, H1 2014 14
Number of Products under Development by Companies, H1 2014 15
Comparative Analysis by Late Stage Development, H1 2014 20
Comparative Analysis by Clinical Stage Development, H1 2014 21
Comparative Analysis by Early Stage Products, H1 2014 22
Assessment by Monotherapy Products, H1 2014 60
Number of Products by Top 10 Target, H1 2014 61
Number of Products by Stage and Top 10 Target, H1 2014 62
Number of Products by Top 10 Mechanism of Action, H1 2014 64
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 65
Number of Products by Top 10 Route of Administration, H1 2014 67
Number of Products by Stage and Top 10 Route of Administration, H1 2014 68
Number of Products by Top 10 Molecule Type, H1 2014 69
Number of Products by Stage and Top 10 Molecule Type, H1 2014 70
